Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Garrett Motion Inc. (Nasdaq: GTX) announced today its common stock has commenced trading on the Nasdaq Global Select Market, which has the highest listing standards at the exchange, under the...
NEW YORK, April 15, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders...
-- Merger will combine Oncternal’s clinical stage oncology pipeline and expertise with GTx’s preclinical Selective Androgen Receptor Degrader (SARD) program for castration-resistant prostate...
NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders...
GTx, Inc. (Nasdaq: GTXI) today reported financial results for the third quarter ended September 30, 2018, and provided a corporate update. “During the quarter, we turned our focus to the...
GTx, Inc. (Nasdaq: GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal...
GTx, Inc. (Nasdaq: GTXI) today announced that Robert J. Wills, PhD, Executive Chairman, and other senior executive management team members will present a company overview at the Baird 2018...
-- Completed patient enrollment in the ASTRID Trial, a Phase 2 double-blinded, placebo-controlled clinical trial of enobosarm in Stress Urinary Incontinence -- -- Top-line results from...
GTx, Inc. (Nasdaq: GTXI) today announced that it has been added to the Russell 3000® Index as part of the Russell U.S. Indexes annual reconstitution. The addition will take effect after the...
GTx, Inc. (Nasdaq: GTXI) today announced that Robert J. Wills, PhD, Executive Chairman, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Thursday, June...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
